A phase 3, double-blind, placebo-controlled study of quizartinib administered in combination with induction and consolidation chemotherapy, and administered as continuation therapy in subjects 18 to 75 years old with newly diagnosed FLT3-ITD (+) acute myeloid leukemia (QuANTUM First). NCT02668653
A randomized, double-blind, placebo controlled phase 3 study of venetoclax in combination with azacitidine versus azacitidine in treatment naïve subjects with acute myeloid leukemia who are ineligible for standard induction therapy. NCT02993523
Aboudalle I et al. A phase IB/II study of the BCL-2 inhibitor venetoclax in combination with standard intensive AML induction/consolidation therapy with FLAG-IDA in patients with newly diagnosed or relapsed/refractory AML. Proc ASH 2019;Abstract 176.
Burchert A et al. Sorafenib as maintenance therapy post allogeneic stem cell transplantation for FLT3-ITD positive AML: Results from the randomized, double-blind, placebo-controlled multicentre Sormain trial. Proc ASH 2018;Abstract 661.
Cluzeau T et al. APR-246 combined with azacitidine (AZA) in TP53 mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). A Phase 2 study by the Groupe Francophone Des Myélodysplasies (GFM). Proc ASH 2019;Abstract 677.
Cortes JE et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QUANTUM-R): A multicenter, randomized, controlled, open-label, phase 3 trial. Lancet Oncol 2019;20(7):984-97. Abstract
DiNardo CD et al. Venetoclax combined with decitabine or azacitidine in treatment-naïve, elderly patients with AML. Blood 2019;133(1):7-17. Abstract
Garcia-Manero G et al. A phase II study of nivolumab or ipilimumab with or without azacitidine for patients with myelodysplastic syndrome (MDS). Proc ASH 2018;Abstract 465.
Gibson CJ et al. Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma. J Clin Oncol 2017:35(14):1598-605. Abstract
Lancet JE et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol 2018;36(26):2684-92. Abstract
Perl AE et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med 2019;381(18):1728-40. Abstract
Ritchie EK et al. The relationship between hospitalization and patient-reported outcomes (PROs) in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the phase 3 Admiral study. Proc ASH 2019;Abstract 1332.
Sallman DA et al. Phase 2 results of APR-246 and azacitidine (AZA) in patients with TP53 mutant myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia (AML). Proc ASH 2019;Abstract 676.
Sallman DA et al. The first-in-class anti-CD47 antibody magrolimab (5F9) in combination with azacitidine is effective in MDS and AML patients: Ongoing phase 1b results. Proc ASH 2019;Abstract 569.
Smith CC et al. Emerging mutations at relapse in patients with FLT3-mutated relapsed/refractory acute myeloid leukemia who received gilteritinib therapy in the phase 3 Admiral trial. Proc ASH 2019;Abstract 14.
Steensma DP. Clinical consequences of clonal hematopoiesis of indeterminate potential. Blood Adv 2018;2(22):3404-10. Abstract
Stone RM et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 2017;377(5):454-64. Abstract
Swaminathan M. The combination of quizartinib with azacitidine or low dose cytarabine is highly active in patients with FLT3-ITD mutated AML: Interim report of a Phase I/II trial. Proc ASH 2017;Abstract 723.
Wei AH et al. The QUAZAR AML-001 maintenance trial: Results of a phase III international, randomized, double-blind, placebo-controlled study of CC-486 (oral formulation of azacitidine) in patients with acute myeloid leukemia (AML) in first remission. Proc ASH 2019;Abstract LBA-3.
Zeidan AM et al. Efficacy and safety of azacitidine (AZA) in combination with the anti-PD-L1 durvalumab (durva) for the front-line treatment of older patients (pts) with acute myeloid leukemia (AML) who are unfit for intensive chemotherapy (ic) and pts with higher-risk myelodysplastic syndromes (HR-MDS): Results from a large, international, randomized phase 2 study. Proc ASH 2019;Abstract 829.